GLAUCOMA Clinical Trial
Diurnal fluctuations of intraocular pressure in EX-Press Valve Blebs in Glaucoma Patients
Intraocular pressure (IOP) reduction is the mainstay of glaucoma management. (1) Open-angle
glaucoma (OAG) is generally managed by decreasing the intraocular pressure (IOP) to a level
that the physician believes will prevent further glaucomatous damage. However, in a
significant proportion of patients, the visual fields continue to deteriorate in spite of
office pressures within the range of normal values (8). It has been suggested that the
progressive damage in some cases could be caused by peaks of IOP or diurnal IOP variability
not detected by tonometry during office hours. It is possible that certain drugs or surgical
interventions are more effective than others in dampening these fluctuations. The purpose of
our study is to compare the diurnal IOP fluctuations in glaucoma patients treated with
medications or Ex-press filtration surgery.
Diurnal fluctuations of intraocular pressure in EX-Press Valve Blebs in Glaucoma Patients
Department of Ophthalmology, Hillel-Yaffe Medical Center, affiliated with the Bruce
Rappaport School of Medicine, The Technion, Haifa, Israel
Introduction:
Intraocular pressure (IOP) reduction is the mainstay of glaucoma management. (1) Medication
alone is sometimes not sufficient to reduce excessively high IOP, and pharmaceutical
intolerance may develop or damage can occur to the optic nerve, warranting surgical
intervention. (2) The filtering bleb is considered to be the cornerstone of IOP control
after glaucoma filtration surgery drainage device implantation. (3) It enables the flow of
the aqueous humor from the anterior chamber to the subconjunctiva, episclera, sclera and
choroid, thereby lowering the IOP. (4-6) Filtration and drainage devices, such as the
EX-Press device (Alcon Laboratories, Fort Worth, Texas, USA), offer a surgical alternative
to glaucoma medical therapy. (7) Open-angle glaucoma (OAG) is generally managed by
decreasing the intraocular pressure (IOP) to a level that the physician believes will
prevent further glaucomatous damage. However, in a significant proportion of patients, the
visual fields continue to deteriorate in spite of office pressures within the range of
normal values (8). It has been suggested that the progressive damage in some cases could be
caused by peaks of IOP or diurnal IOP variability not detected by tonometry during office
hours. (9, 10) In another study, Asrani et al. (11) showed that IOP fluctuations are an
independent risk factor in patients with glaucoma and as such may need to be treated
specifically. It is possible that certain drugs or surgical interventions are more effective
than others in dampening these fluctuations. The purpose of our study is to compare the
diurnal IOP fluctuations in glaucoma patients treated with medications or Ex-press
filtration surgery.
Materials and Methods The study will include 20 open-angle glaucoma (OAG) patients underwent
Ex-Press filtration surgery, and 20 OAG patients treated with medications alone. All
patients will have 12 IOP measurements with 2 hours interval, starting at 10 AM until 10 AM
of the following morning.
ICARE® PRO tonometer (Icare Finland Oy, Espoo, Finland) will be used for the measurement of
IOP. The rebound motion of its light weighted probe will be recorded during contact of the
probe with the cornea. (12, 13) The rate of deceleration of the probe is a function of IOP.
The ICARE® PRO has a built-in inclination sensor that allows downward measurement of the eye
in the supine position as well as in the normal upright sitting position. ICARE® PRO allows
for measurement of IOP in the seated and supine positions. During IOP recording, patients
will be supine or upright, and the tip of the probe will be applied perpendicular to the
cornea. Two markers engraved on the piston of the probe indicated its ideal positioning. The
reliability of the measurement is displayed on the ICARE® PRO tonometer screen and guided
our measurements.
Fluctuations in IOP will be compared between the Ex-press filtration surgery eye and the
fellow (intra-group comparison). Inter-group comparison of IOP fluctuation will be performed
between the Ex-press filtration surgery eye and medically treated eye of different patients.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A |